Evidence map›Paper›PMID 28292162›Full record

ArticleThe Pan African medical journal2016

[Primary large cell neuroendocrine carcinoma of the breast: a rare tumor in humans].

Fatima Safini, Zineb Bouchbika, Zineb Bennani, Sara Belkheiri, Hicham El Attar, Nadia Benchakroun, Hassan Jouhadi, Nezha Tawfiq, Souha Sahraoui, Abdellatif Benider

Open access · goldAbstract readCase Reports
In one paragraph

Article in The Pan African medical journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Fatima SafiniService d'Oncologie et de Radiothérapie, CHU Ibn Rochd, Casablanca, Maroc.
Zineb BouchbikaService d'Oncologie et de Radiothérapie, CHU Ibn Rochd, Casablanca, Maroc.
Zineb BennaniService d'Oncologie et de Radiothérapie, CHU Ibn Rochd, Casablanca, Maroc.
Sara BelkheiriService d'Oncologie et de Radiothérapie, CHU Ibn Rochd, Casablanca, Maroc.
Hicham El AttarLaboratoire d'Etude Anatomopathologique Moulay Driss Premier, Casablanca, Maroc.
Nadia BenchakrounService d'Oncologie et de Radiothérapie, CHU Ibn Rochd, Casablanca, Maroc.
Hassan JouhadiService d'Oncologie et de Radiothérapie, CHU Ibn Rochd, Casablanca, Maroc.
Nezha TawfiqService d'Oncologie et de Radiothérapie, CHU Ibn Rochd, Casablanca, Maroc.
Souha SahraouiService d'Oncologie et de Radiothérapie, CHU Ibn Rochd, Casablanca, Maroc.
Abdellatif BeniderService d'Oncologie et de Radiothérapie, CHU Ibn Rochd, Casablanca, Maroc.
Hôpital 20 Août · MAPremier University · BD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primitive large cell neuroendocrine tumor of the breast is an extremely rare entity. Less than ten cases have been reported in the literature. We report a new case of a 61-year old male patient presenting with locally advanced tumor of the right breast, immediately metastasized to the lungs and pleura, staged cT4bN1M1. The patient received eight cycles of Docetaxel-based chemotherapy every 21 days, with a good clinical and radiological response (>50%), followed by adjuvant tamoxifen with disease stabilization for 18 months. Immunohistochemistry is still essential to determine the neuroendocrine nature of this tumor. Treatment is not well codified due to the rarity of this type of cancer.

Indexed as

Antineoplastic AgentsBreast Neoplasms, MaleCarcinoma, NeuroendocrineChemotherapy, AdjuvantDocetaxelHumansImmunohistochemistryLung NeoplasmsMaleMiddle AgedNeoplasm StagingPleural NeoplasmsTamoxifenTaxoidsTreatment OutcomeAntineoplastic AgentsDocetaxelTamoxifenTaxoidsBreast cancerlarge cellsneuroendocrine

Identifiers

PMID28292162
PMCPMC5326194
OpenAlexW2558075420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.